DNLI
NASDAQ
US
Denali Therapeutics Inc. - Common Stock
$20,65
▲ +$0,97
(+4,93%)
Vol. 1.6M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$2.6B
ROE
-40,8%
Margine
-36,5%
D/E
0,60
Beta
0,98
52W
$11–$24
Consenso Wall Street
25 analisti · Apr 202611
Acquisto forte
12
Compra
2
Mantieni
0
Vendi
0
Vendita forte
92,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17,3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
DYN
Dyne Therapeutics Inc
$3.2B
TNGX
Tango Therapeutics Inc
$1.2B
TWST
Twist Bioscience Corp
$1.9B
CPRX
Catalyst Pharmaceuticals Inc
P/E 13,2
$2.9B
ARQT
Arcutis Biotherapeutics Inc
$3.6B
VERA
Vera Therapeutics, Inc
$3.5B
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,76 | $-0,73 | +$0,03 |
| Set 2025 | $-0,77 | $-0,74 | +$0,03 |
| Giu 2025 | $-0,73 | $-0,72 | +$0,01 |
| Mar 2025 | $-0,70 | $-0,78 | $-0,08 |
Ricavi e utili trimestrali
| Trimestre | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$114.8M | -$133.0M | -$124.1M | -$126.9M | -$128.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -40.8% | -31.4% | -31.4% | -31.4% | -40.8% | -40.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -36.5% | -36.5% | -36.5% | -36.5% | -36.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.54 | 0.54 | 0.54 | 0.54 | 0.60 | 0.60 |
| Current Ratio | 10.27 | 10.27 | 10.27 | 10.27 | 9.79 | 9.79 |
Rapporti chiave
ROA (TTM)
-36,4%
P/S (TTM)
7,57
P/B
2,4
EPS (TTM)
$-2,81
CF/Share
$-0,77
52W High
$24,35
52W Low
$10,57
$10,57
Intervallo 52 settimane
$24,35
Salute finanziaria
Flusso di cassa libero
-$100.1M
Debito netto
-$168.6M
Liquidità
$205.3M
Debito totale
$36.8M
Aggiornato al Dic 31, 2025
Як DNLI виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка DNLI vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
7,6
▼
41%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
2,4
▼
3%
sotto
peer
(2,5)
vs Peer
vs Settore
Valore equo
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість DNLI vs аналоги Biotechnology
ROE
-40,8%
▲
39%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
-36,5%
▲
87%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-36,4%
▲
22%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя DNLI vs аналоги Biotechnology
D/E ratio
0,6
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
In linea
Поточна ліквідність
9,8
▲
121%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
1,0
▲
1%
sopra
peer
(1,0)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів DNLI
DNLI
Mediana peer
Industria
DNLI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
DNLI vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
WATTS RYAN J
Chief Executive Officer · Gen 06
35198 shs
SCHUTH ALEXANDER O
Chief Financial Officer · Gen 06
17218 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 33,0%Vanguard Group Inc
8,23%
$237.1M
Blackrock Inc.
8,02%
$230.9M
BAILLIE GIFFORD & CO
7,76%
$223.6M
T. Rowe Price Investment Ma…
4,57%
$131.7M
Temasek Holdings (Private) …
4,42%
$127.4M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora